Treatment of rheumatoid arthritis: Unraveling the conundrum

Journal of Autoimmunity

Volumn 65, Issue , 2015, Pages 1-18

  Zampeli, Evangelia ^a   Vlachoyiannopoulos, Panayiotis G ^a   Tzioufas, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Biologic agents; DMARDs; Pathophysiology; Rheumatoid arthritis; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; APRIL PROTEIN; B CELL ACTIVATING FACTOR; BARICITINIB; BELIMUMAB; BRODALUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FOSTAMATINIB; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; IXEKIZUMAB; JANUS KINASE; PROTEIN KINASE SYK; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; RUXOLITINIB; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; AUTOANTIGEN; BIOLOGICAL PRODUCT; CYTOKINE; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; ENVIRONMENTAL FACTOR; FIBROBLAST; HEREDITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; ECONOMICS; GENETICS; IMMUNOLOGY; METABOLISM; QUALITY OF LIFE; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; B-LYMPHOCYTES; BIOLOGICAL PRODUCTS; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; T-LYMPHOCYTES;

EID: 84949992542     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.10.003     Document Type: Review

References (213)

1. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011, 365:2205-2219.
2. Smolen J.S., Aletaha D., Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. Nat. Rev. Rheumatol. 2012, 8:235-243.
3. Smolen J.S., Breedveld F.C., Burmester G.R., Bykerk V., Dougados M., Emery P., et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 2015 May 12, pii: annrheumdis-2015-207524, (Epub ahead of print). 10.1136/annrheumdis-2015-207524.
4. Rodnan G.P., Benedek T.G. The early history of antirheumatic drugs. Arthritis Rheum. 1970, 13:145-165.
5. Forestier J. Rheumatoid arthritis and its treatment by gold salts. J. Lab. Clin. Med. 1935, 20:827-840.
6. Gold therapy in rheumatoid arthritis. Final report of a multicentre controlled trial. Ann. Rheum. Dis. 1961, 20:315-334. Empire Rheumatism Council.
7. Gold therapy in rheumatoid arthritis: report of a multicentre controlled trial. Ann. Rheum. Dis. 1960, 19:95-119. Empire Rheumatism Council.
8. Felson D.T., Anderson J.J., Meenan R.F. Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum. 1990, 33:140-149.
9. Wolfe F. The curious case of intramuscular gold. Rheum. Dis. Clin. North Am. 1993, 19:173-187.
10. Moutsopoulos H.M., Skopouli F.N., Sarras A.K., Tsampoulas C., Mavridis A.K., Constantopoulos S.H., et al. Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann. Rheum. Dis. 1985, 44:215-219.
11. Drosos A.A., Christou L., Galanopoulou V., Tzioufas A.G., Tsiakou E.K. D-penicillamine induced myasthenia gravis: clinical, serological and genetic findings. Clin. Exp. Rheumatol. 1993, 11:387-391.
12. Tzartos S.J., Morel E., Efthimiadis A., Bustarret A.F., D'Anglejan J., Drosos A.A., et al. Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis. Clin. Exp. Immunol. 1988, 74:80-86.
13. Case J.P. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am. J. Ther. 2001, 8:123-143. (A).
14. Svartz N. Salazopyrin, a new sulfaniliamide preparation: A. Therapeutic results in rheumatic polyarthritis; B. Therapeutic results in ulcerative colitis; C. Toxic manifestations in treatment with sulfanilamide preparations. Acta Med. Scand. 1942, 110:577-598.
15. Svartz N. The treatment of rheumatic polyarthritis with acid azo compounds. Rheumatism 1948, 4:56-60.
16. Bird H.A. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid-which is the active moiety in rheumatoid arthritis?. Br. J. Rheumatol. 1995, 34(Suppl. 2):16-19.
17. Neumann V.C., Taggart A.J., Le Gallez P., Astbury C., Hill J., Bird H.A. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J. Rheumatol. 1986, 13:285-287.
18. Azad K.A., Piris J., Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977, 2:892-895.
19. Gadangi P., Longaker M., Naime D., Levin R.I., Recht P.A., Montesinos M.C., et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 1996, 156:1937-1941.
20. Morabito L., Montesinos M.C., Schreibman D.M., Balter L., Thompson L.F., Resta R., et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Investig. 1998, 101:295-300.
21. Danis V.A., Franic G.M., Rathjen D.A., Laurent R.M., Brooks P.M., et al. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann. Rheum. Dis. 1992, 51:946-950.
22. Saag K.G. Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. Am. J. Med. 1997, 103:31S-39S.
23. Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?. Ann. Rheum. Dis. 2011, 70:1881-1883.
24. Van der Goes M.C., Jacobs J.W., Boers M., Andrews T., Blom-Bakkers M.A., Buttgereit F., et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann. Rheum. Dis. 2010, 69:1913-1919.
25. Hoes J.N., Jacobs J.W., Boers M., Boumpas D., Buttgereit F., Caeyers N., et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 2007, 66:1560-1567.
26. Buttgereit F., Doering G., Schaeffler A., Witte S., Sierakowski S., Gromnica-Ihle E., et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomized controlled trial. Lancet 2008, 371:205-214.
27. Buttgereit F., Gibofsky A. Delayed-release prednisone - a new approach to an old therapy. Expert Opin. Pharmacother. 2013, 14:1097-1106.
28. Buttgereit F., Mehta D., Kirwan J., Szechinski J., Boers M., Alten R.E., et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann. Rheum. Dis. 2013, 72:204-210.
29. Alarcon G.S., López-Méndez A., Walter J., Boerbooms A.M., Russell A.S., Furst D.E., et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J. Rheumatol. 1992, 19:1868-1873.
30. Westedt M.L., Dijkmans B.A., Hermans J. Comparison of azathioprine and methotrexate in rheumatoid arthritis: an open-randomized clinical study. Rev. Rheum. 1994, 61:591-597.
31. Willkens R.F., Sharp J.T., Stablein D., Marks C., Wortmann R. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum. 1995, 38:1799-1806.
32. Farber S., Diamond L.K., Mercer R.D. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N. Engl. J. Med. 1948, 238:787-793.
33. Gubner R., August S., Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effects of aminopterin in rheumatoid arthritis and psoriasis. Am. J. Med. Sci. 1951, 22:176-182.
34. Willkens R.F., Watson M.A. Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J. Lab. Clin. Med. 1982, 100:314-321.
35. Hoffmeister R.T. Methotrexate therapy in rheumatoid arthritis: 15 years' experience. Am. J. Med. 1983, 75:69-73.
36. Felson D.T., Anderson J.J., Meenan R.F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta analyses. Arthritis Rheum. 1990, 33:1449-1461.
37. Drosos A.A., Tsifetaki N., Tsiakou E.K., Timpanidou M., Tsampoulas C., Tatsis C.K., et al. Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin. Exp. Rheumatol. 1997, 15:263-267.
38. Hirata S., Matsubara T., Saura R., Tateishi H., Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 1989, 32:1065-1073.
39. Sandoval D.M., Alarcon G.S., Morgan S.L. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br. J. Rheumatol. 1995, 34(Suppl. 2):49-56.
40. Morgan S.L., Baggott J.E., Vaughn W.H., Austin J.S., Veitch T.A., Lee J.Y., et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann. Intern. Med. 1994, 121:833-841.
41. Buckley L.M., Vacek P.M., Cooper S.M. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J. Rheumatol. 1990, 17:1158-1161.
42. Zitnik R.J., Cooper J.A. Pulmonary disease due to antirheumatic agents. Clin. Chest Med. 1990, 11:139-150.
43. Alarcon G.S., remer J.M., Macaluso M., Weinblatt M.E., Cannon G.W., Palmer W.R., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann. Intern. Med. 1997, 127:356-364.
44. Visser K., van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 2009, 68:1094-1099.
45. Marbet U.A., Graf U., Mihatsch M.J., Gratwohl A., Müller W., Thiel G. Renal side effects of treatment with cyclosporin A in rheumatoid arthritis and after bone marrow transplantation. Schweiz. Med. Wochenschr. 1980, 110:2017-2020.
46. Shevach E.M. The effects of cyclosporin A on the immune system. Annu. Rev. Physiol. 1985, 3:397-423.
47. Tsokos G.C. Immunomodulatory treatment in patients with rheumatic diseases: mechanisms of action. Semin. Arthritis Rheum. 1987, 17:24-38.
48. Case J.P. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: the newer drugs and drug strategies. Am. J. Ther. 2001, 8:163-179. (B).
49. Xu X., Blinder L., Shen J., Gong H., Finnegan A., Williams J.W., et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J. Immunol. 1997, 159:167-174.
50. Faarvang K.L., Egsmose C., Kryger P., Pødenphant J., Ingeman-Nielsen M., Hansen T.M. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann. Rheum. Dis. 1993, 52:711-715.
51. Ferraz M.B., Pinheiro G.R., Helfenstein M., Albuquerque E., Rezende C., Roimicher L., et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. Scand. J. Rheumatol. 1994, 23:231-236.
52. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008, 58:15-25. National Arthritis Data Workgroup.
53. Silman A.J., Pearson J.E. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002, 4(Suppl. 3):S265-S272.
54. Drosos A.A., Lanchbury J.S., Panayi G.S., Moutsopoulos H.M. Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum. 1992, 35:745-748.
55. Boki K.A., Panayi G.S., Vaughan R.W., Drosos A.A., Moutsopoulos H.M., Lanchbury J.S. HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients. Arthritis Rheum. 1992, 35:749-755.
56. Paula F.S., Alves J.D. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biologics 2014, 8:1-12.
57. Takemura S., Klimiuk P.A., Brown A., Goronzy J.J., Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 2001, 167:4710-4718.
58. Van de Veerdonk F.L., Lauwerys B., Marijnissen R.J., Timmermans K., Di Padova F., Koenders M.I., et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011, 63:1507-1516.
59. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
60. Steiner G., Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 2002, 4(Suppl. 2):S1-S5.
61. Moura R.A., Cascão R., Perpétuo I., Canhão H., Vieira-Sousa E., Mourão A.F., et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology 2011, 50:278-282.
62. Ohata J., Zvaifler N.J., Nishio M., Boyle D.L., Kalled S.L., Carson D.A., et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J. Immunol. 2005, 174:864-870.
63. Koenders M.I., Lubberts E., van de Loo F.A., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J. Immunol. 2006, 176:6262-6269.
64. Dienz O., Rincon M. The effects of IL-6 on CD4 T cell responses. Clin. Immunol. 2009, 130:27-33.
65. Kishimoto T. IL-6: from its discovery to clinical applications. Int. Immunol. 2010, 22:347-352.
66. Raza K., Falciani F., Curnow S.J., Ross E.J., Lee C.Y., Akbar A.N., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 2005, 4:R784-R795.
67. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007, 7:429-442.
68. Gernero P., Thompson E., Woodworth T., Smolen J.S. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum. 2010, 62:33-43.
69. Eder K., Baffy N., Falus A., Fulop A.K. The major inflammatory mediator interleukin-6 and obesity. Inflamm. Res. 2009, 11:727-736.
70. Lee H.Y., Kim S.D., Baek S.H., Choi J.H., Cho K.H., Zabel B.A., et al. Serum amyloid A stimulates macrophage foam cell formation via lectin-like oxidized low-density lipoprotein receptor 1 upregulation. Biochem. Biophys. Res. Commun. 2013, 433:18-23.
71. Panichi V., Migliori M., De Pietro S., Taccola D., Andreini B., Metelli M.R., et al. The link of biocompatibility to cytokine production. Kidney Int. 2000, 58:96-103.
72. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
73. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 1995, 332:1351-1362.
74. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res. Ther. 2007, 9:203.
75. Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y., Athanasou N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003, 32:1-7.
76. Lally F., Smith E., Filer A., Stone M.A., Shaw J.S., Nash G.B., et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. 2005, 52:3460-3469.
77. Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K., et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003, 48:1521-1529.
78. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 2004, 113:1271-1276.
79. de Benedetti F., Rucci N., Del Fattore A., Peruzzi B., Paro R., Longo M., et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006, 54:3551-3563.
80. Nalbandian A., Crispin J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin. Exp. Immunol. 2009, 157:209-215.
81. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
82. Weinblatt M.E., Genovese M.C., Ho M., Hollis S., Rosiak-Jedrychowicz K., Kavanaugh A., et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014, 66:3255-3264.
83. Platt A.M., Benson R.A., McQueenie R., Butcher J.P., Braddock M., Brewer J.M., et al. The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4[U+207A] T cell-priming capacity of dendritic cells. Rheumatology (Oxford) 2015, 54:169-177.
84. Geahlen R.L. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol. Sci. 2014, 35:414-422.
85. Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res. Ther. 2010, 12:111.
86. Daridon C., Burmester G.R., Dörner T. Anticytokine therapy impacting on B cells in autoimmune diseases. Curr. Opin. Rheumatol. 2009, 21:205-210.
87. Boyle D.L., Soma K., Hodge J., Kavanaugh A., Mandel D., Mease P., et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann. Rheum. Dis. 2015, 74:1311-1316.
88. Smolen J.S., Aletaha D., Koeller M., Weisman M.H., Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874.
89. Hamel K., Doodes P., Cao Y., Wang Y., Martinson J., Dunn R., et al. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J. Immunol. 2008, 7:4994-5003.
90. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004, 25:2572-2581.
91. Moura R.A., Graça L., Fonseca J.E. To B or not to B: the conductor of rheumatoid arthritis orchestra. Clin. Rev. Allergy Immunol. 2012, 43:281-291.
92. Buch M.H., Smolen J.S., Betteridge N., Breedveld F.C., Burmester G., Dörner T., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2011, 70:909-920.
93. Martinez-Gamboa L., Brezinschek H.P., Burmester G.R., Dörner T. Immunopathologic role of B lymphocytes in rheumatoid arthritis: rational of B cell-directed therapy. Autoimmun. Rev. 2006, 5:437-442.
94. Nakou M., Katsikas G., Sidiropoulos P., Bertsias G., Papadimitraki E., Raptopoulou A., et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res. Ther. 2009, 11:R131.
95. Kavanaugh A., Rosengren S., Lee S.J., et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann. Rheum. Dis. 2008, 67:402-408.
96. Marston B., Palanichamy A., Anolik J.H. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 2010, 22:307-315.
97. Sellam J., Hendel-Chavez H., Rouanet S., Abbed K., Combe B., Le Loët X., et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011, 63:933-938.
98. Isaacs J.D., Cohen S.B., Emery P., Tak P.P., Wang J., Lei G., et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis. 2013, 72:329-336.
99. Dörner T., Radbruch A., Burmester G.R. B-cell-directed therapies for autoimmune disease. Nat. Rev. Rheumatol. 2009, 8:433-441.
100. Tak P.P., Rigby W.F., Rubbert-Roth A., Peterfy C.G., van Vollenhoven R.F., Stohl W., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 2011, 70:39-46.
101. Emery P., Deodhar A., Rigby W.F., Isaacs J.D., Combe B., Racewicz A.J., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE). Ann. Rheum. Dis. 2010, 69:1629-1635.
102. Rubbert-Roth A., Tak P.P., Zerbini C., Tremblay J.L., Carreño L., Armstrong G., et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 2010, 49:1683-1693.
103. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54:2793-2806.
104. Keystone E.C., Cohen S.B., Emery P., Kremer J.M., Dougados M., Loveless J.E., et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J. Rheumatol. 2012, 39:2238-2246.
105. Gomez-Reino J.J., Maneiro J.R., Ruiz J., et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR study. Ann. Rheum. Dis. 2012, 71:1861-1864.
106. Soliman M.M., Hyrich K.L., Lunt M., Watson K.D., Symmons D.P., Ashcroft D.M. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res. 2012, 64:1108-1115.
107. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006, 54:1390-1400.
108. Chatzidionysiou K., Lie E., Nasonov E., Lukina G., Hetland M.L., Tarp U., et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann. Rheum. Dis. 2012, 71:374-377.
109. Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Kremer J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. Hob. 2012, 64:625-639.
110. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006, 144:865-876.
111. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, doubleblind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2008, 67:1096-1103.
112. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST study. Ann. Rheum. Dis. 2011, 70:2003-2007.
113. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005, 353:1114-1123.
114. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 2000, 343:1594-1602. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
115. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004, 50:3432-3443. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.
116. Westhovens R., Houssiau F., Joly J., Everitt D.E., Zhu Y., Sisco D., et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. J. Rheumatol. 2006, 33:847-853.
117. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 1999, 130:478-486.
118. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 1999, 340:253-259.
119. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 2000, 343:1586-1593.
120. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004, 363:675-681.
121. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
122. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48:35-45.
123. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004, 63:508-516.
124. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004, 50:1400-1411.
125. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 2003, 30:2563-2571.
126. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006, 54:26-37.
127. Kay J., Matteson E.L., Dasgupta B., Nash P., Durez P., Hall S., et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008, 58:964-975.
128. Smolen J.S., Kay J., Doyle M.K., Landewé R., Matteson E.L., Wollenhaupt J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221.
129. Keystone E.C., Genovese M.C., Klareskog L., Hsia E.C., Hall S.T., Miranda P.C., et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann. Rheum. Dis. 2009, 68:789-796.
130. Emery P., Fleischmann R.M., Moreland L.W., Hsia E.C., Strusberg I., Durez P., et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009, 60:2272-2283.
131. Keystone E., Heijde Dv, Mason D., Landewé R., Vollenhoven R.V., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum. 2008, 58:3319-3329.
132. Smolen J., Landewé R.B., Mease P., Brzezicki J., Mason D., Luijtens K., et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann. Rheum. Dis. 2009, 68:797-804.
133. Fleischmann R., Vencovsky J., van Vollenhoven R.F., Borenstein D., Box J., Coteur G., et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 2009, 68:805-811.
134. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
135. Emery P., Keystone E., Tony H.P., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicenter randomised placebo-controlled trial. Ann. Rheum. Dis. 2008, 67:1516-1523.
136. Yazici Y., Curtis J.R., Ince A., Baraf H., Malamet R.L., Teng L.L., et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann. Rheum. Dis. 2012, 71:198-205.
137. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46:614-624.
138. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998, 41:2196-2204.
139. Lafferty K.J., Prowse S.J., Simeonovic C.J., Warren H.S. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1983, 1:143-173.
140. Mueller D.L., Jenkins M.K., Schwartz R.H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 1989, 7:445-480.
141. Linsley P.S., Brady W., Grosmaire L., Aruffo A., Damle N.K., Ledbetter J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 1991, 173:721-730.
142. Koulova L., Clark E.A., Shu G., Dupont B. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+T cells. J. Exp. Med. 1991, 173:759-762.
143. Young J.W., Koulova L., Soergel S.A., Clark E.A., Steinman R.M., Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J. Clin. Investig. 1992, 90:229-237.
144. Linsley P.S., Greene J.L., Brady W., Bajorath J., Ledbetter J.A., Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1:793-801.
145. Peach R.J., Bajorath J., Brady W., Leytze G., Greene J., Naemura J., et al. Complementarity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 1994, 180:2049-2058.
146. Greene J.L., Leytze G.M., Emswiler J., Peach R., Bajorath J., Cosand W., et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulates T cell costimulatory interactions. J. Biol. Chem. 1996, 271:26762-26771.
147. Buch M.H., Boyle D.L., Rosengren S., Saleem B., Reece R.J., Rhodes L.A., et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann. Rheum. Dis. 2009, 68:1220-1227.
148. Weisman M.H., Durez P., Hallegua D., Aranda R., Becker J.C., Nuamah I., et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J. Rheumatol. 2006, 33:2162-2166.
149. Von Kempis J., Dudler J., Hasler P., Kyburz D., Tyndall A., Zufferey P., et al. Use of abatacept in rheumatoid arthritis. Swiss Med. Wkly. 2012, 142:w13581.
150. Gottenberg J.E., Ravaud P., Cantagrel A., Combe B., Flipo R.M., Schaeverbeke T., et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann. Rheum. Dis. 2012, 71:1815-1819.
151. Schiff M., Pritchard C., Huffstutter J.E., Rodriguez-Valverde V., Durez P., et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 2009, 68:1708-1714.
152. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000, 47:119-125.
153. Dutta S., Ahmad Y. The efficacy and safety of tacrolimus in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 2011, 3:283-291.
154. Dinarello C.A., Cannon J.G., Wolff S.M., Bernheim H.A., Beutler B., Cerami A., et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 1986, 163:1433-1450.
155. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10:4025-4031.
156. Chu C.Q., Field M., Feldmann M., Maini R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34:1125-1132.
157. Smolen J.S., Han C., Bala M., Maini R.N., Kalden J.R., van der Heijde D., et al. Group AS: evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005, 52:1020-1030.
158. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002, 46:1443-1450.
159. Smolen J.S., Nash P., Durez P., Hall S., Ilivanova E., Irazoque-Palazuelos F., et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013, 381:918-929.
160. Van Vollenhoven R.F., Østergaard M., Leirisalo-Repo M., Uhlig T., Jansson M., Klackenberg Å.,K.H. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-Armed, double-blind clinical trial. The DOSERA study. EULAR Congress 2013; Madrid, Spain 2013.
161. Fautrel B., Pham T., Morel J., Alfaiate T., Dernis E., Gaudin P., et al. Impact of progressive spacing of TNF-blocker injections on signs and symptoms of rheumatoid arthritis patients in DAS28 remission: the STRASS randomized controlled trial. EULAR Congress 2013, Madrid, Spain; 2013.
162. Burmester G.R., Mariette X., Montecucco C., Monteagudo-Saez I., Malaise M., Tzioufas A.G., et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. 2007, 66:732-739.
163. Bombardieri S., Ruiz A.A., Fardellone P., Geusens P., McKenna F., Unnebrink K., et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007, 46:1191-1199. Research in Active Rheumatoid Arthritis (ReAct) Study Group.
164. Smolen J.S., Emery P., Fleischmann R., van Vollenhoven R.F., Pavelka K., Durez P., et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomized controlled OPTIMA trial. Lancet 2014, 383:321-332.
165. Tanak Y., Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann. Rheum. Dis. 2014, 73:9.
166. Smolen J.S., Landewé R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 2014, 73:492-509.
167. Burmester G.R., Rubbert-Roth A., Cantagrel A., Hall S., Leszczynski P., Feldman D., et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann. Rheum. Dis. 2014, 73:69-74.
168. Ogata A., Tanimura K., Sugimoto T., Inoue H., Urata Y., Matsubara T., et al. A phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI). Arthritis Care Res. 2014, 66:344-354. Musashi Study Investigators.
169. Guidelli G.M., Barskova T., Brizi M.G., Lepri G., Parma A., Talarico R., et al. One year in review: novelties in the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2015, 33:102-108.
170. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., Duff G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988, 2:706-709.
171. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998, 41:2196-2204.
172. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181:787-796.
173. O'Dell J.R. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 2004, 350:2591-2602.
174. Turkstra E., Ng S.K., Scuffham P.A. A mixed treatment comparison of the short-term efficacy of biologic disease modifying antirheumatic drugs in established rheumatoid arthritis. Curr. Med. Res. Opin. 2011, 27:1885-1897.
175. Sandborg C., Mellins E.D. A new era in the treatment of systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012, 367:2439-2440.
176. Giampietro C., Fautrel B. Anti-interleukin-1 agents in adult onset still's disease. Int. J. Inflam. 2012, 2012:317820.
177. Mor A., Abramson S.B., Pillinger M.H. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin. Immunol. 2005, 115:118-128.
178. Bottini N., Firestein G.S. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat. Rev. Rheumatol. 2013, 9:24-33.
179. Ospelt C., Kyburz D., Pierer M., Seibl R., Kurowska M., Distler O., et al. Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways. Ann. Rheum. Dis. 2004, Suppl. 2, ii90-1.
180. Cho M.L., Ju J.H., Kim H.R., Oh H.J., Kang C.M., Jhun J.Y., et al. Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immunol. Lett. 2007, 108:121-128.
181. Jung Y.O., Cho M.L., Kang C.M., Jhun J.Y., Park J.S., Oh H.J., et al. Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. Immunol. Lett. 2007, 109:21-27.
182. Pierer M., Rethage J., Seibl R., Lauener R., Brentano F., Wagner U., et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J. Immunol. 2004, 172:1256-1265.
183. Brentano F., Schorr O., Gay R.E., Gay S., Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005, 52:2656-2665.
184. Ruth J.H., Haas C.S., Park C.C., Amin M.A., Martinez R.J., Haines G.K., et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 2006, 54:765-778.
185. Patel D.D., Koopmann W., Imai T., Whichard L.P., Yoshie O., Krangel M.S. Chemokines have diverse abilities to form solid phase gradients. Clin. Immunol. 2001, 9:43-52.
186. Nanki T., Lipsky P.E. Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J. Immunol. 2000, 164:5010-5014.
187. Nanki T., Shimaoka T., Hayashida K., Taniguchi K., Yonehara S., Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 2005, 52:3004-3014.
188. Rong C., Hu W., Wu F.R., Cao X.J., Chen F.H. Interleukin-23 as a potential therapeutic target for rheumatoid arthritis. Mol. Cell. Biochem. 2012, 361:243-248.
189. Reparon-Schuijt C.C., van Esch W.J., van Kooten C., Rozier B.C., Levarht E.W., Breedveld F.C., et al. Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. Arthritis Rheum. 2000, 43:1115-1121.
190. Benito-Miguel M., Garcia-Carmona Y., Balsa A., Bautista-Caro M.B., Arroyo-Villa I., Cobo-Ibanez T., et al. IL-15 expression on RA synovial fibroblasts promotes B cell survival. PLoS One 2012, 7:e40620.
191. Alsaleh G., Francois A., Knapp A.M., Schickel J.N., Sibilia J., Pasquali J.L., et al. Synovial fibroblasts promote immunoglobulin class switching by a mechanism involving BAFF. Eur. J. Immunol. 2011, 41:2113-2122.
192. Dechanet J., Merville P., Durand I., Banchereau J., Miossec P. The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. J. Clin. Investig. 1995, 2:456-463.
193. Lee D.M., Kiener H.P., Agarwal S.K., Noss E.H., Watts G.F., Chisaka O., et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007, 315:1006-1010.
194. Bromley M., Woolley D.E. Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum. 1984, 27:857-863.
195. Salliot C., van der H.D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum. Dis. 2009, 68:1100-1104.
196. Pullar T., Hunter J.A., Capell H.A. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br. J. Rheumatol. 1985, 24:269-276.
197. Van Riel P.L., van Gestel A.M., van de Putte L.B. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br. J. Rheumatol. 1995, 34(Suppl. 2):40-42.
198. Ostensen M., Forger F. Management of RA medications in pregnant patients. Nat. Rev. Rheumatol. 2009, 5:382-390.
199. Katz S.J., Russell A.S. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr. Opin. Rheumatol. 2011, 23:278-281.
200. Bili A., Sartorius J.A., Kirchner H.L., Morris S.J., Ledwich L.J., Antohe J.L., et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J. Clin. Rheumatol. 2011, 17:115-120.
201. Morris S.J., Wasko M.C., Antohe J.L., Sartorius J.A., Kirchner H.L., Dancea S., et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res. Hob. 2011, 63:530-534.
202. Van Vollenhoven R.F., Geborek P., Forslind K., Albertsson K., Ernestam S., Petersson I.F., et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012, 379:1712-1720.
203. de Jong P.H., Hazes J.M., Barendregt P.J., Huisman M., van Zeben D., van der Lubbe P.A., et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann. Rheum. Dis. 2013, 72:72-78.
204. Leirisalo-Repo M., Kautiainen H., Laasonen L., Korpela M., Kauppi M.J., Kaipiainen-Seppänen O., et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann. Rheum. Dis. 2013, 72:851-857.
205. Klarenbeek N.B., Güler-Yüksel M., van der Kooij S.M., Han K.H., Ronday H.K., Kerstens P.J., et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann. Rheum. Dis. 2011, 70:1039-1046.
206. Tugwell P., Pincus T., Yocum D., Stein M., Gluck O., Kraag G., et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N. Engl. J. Med. 1995, 333:137-141.
207. Stein M., Pincus T., Yocum D., Tugwell P., Wells G., Gluck O., et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study. Arthritis Rheum. 1997, 40:1843-1851.
208. Kremer J., Genovese M.C., Cannon G.W., Caldwell J.R., Cush J.J., Furst D.E., et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomised, double-blind, placebo-controlled trial. Ann. Intern. Med. 2002, 137:726-733.
209. Kremer J., Genovese M., Cannon G.W., Caldwell J., Cush J., Furst D.E., et al. Combination leflunomide and methotrexate therapy for patients with active rheumatoid arthritis failing methotrexate monotherapy: open label extension of a randomised, double-blind, placebo controlled trial. J. Rheumatol. 2004, 31:1521-1531.
210. O'Dell J.R., Leff R., Paulsen G., Haire C., Mallek J., Eckhoff P.J., et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications. Results of a two-year, randomised, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46:1164-1170.
211. Ferrari M., Onuoha S.C., Pitzalis C. Trojan horses and guided missiles: targeted therapies in the war on arthritis. Nat. Rev. Rheumatol. 2015, 11:328-337.
212. Pitzalis C., Kelly S., Humby F. New learnings on the pathophysiology of RA from synovial biopsies. Curr. Opin. Rheumatol. 2013, 25:334-344.
213. Kelly S., Humby F., Filer A., Ng N., Di Cicco M., Hands R.E., et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Ann. Rheum. Dis. 2015, 74:611-617.